Imexhs Ltd (IME) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Imexhs Ltd stock A$0.35, price A$0.35, upside +1.4%, quality 41 out of 100. Rating: fairly valued. Calculated from audited financials with 9 of our 26 valuation models and 37 quality factors, updated daily.
ImExHS Limited offers cloud-based medical imaging solutions in Australia and internationally. The company operates in two segments: Software and Radiology.
Show moreShow less
It offers medical imaging software that is focused on the development and sale of modular imaging systems, which include information systems for radiology, cardiology, and pathology, as well as a picture archiving and communications system.
The company's solutions include AQUILA, a radiology software solution; ALULA, a pathology software solution; and ANTEROS, a cardiology software solution.
It also provides radiological diagnostic services to hospitals and medical facilities; medical images and radiologists' interpretation; reports to develop artificial intelligence (AI) tools; and outsourced radiology services, as well as teleradiology services.
ImExHS Limited was incorporated in 2001 and is based in Sydney, Australia.
Stock analysis
Imexhs Ltd (IME) currently trades at A$0.3450, while our model-based Fair Value estimate is A$0.3500, so the stock looks roughly fairly valued today (gap 1.4%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of A$0.3500 per share, and 4 of the 9 models we run sit above the A$0.3450 price.
Bear case: the Asset-Based group reads lowest at A$0.1000, and 5 of the 9 models stay below the price. Data coverage for this calculation is low.
Scenario range: A$0.2300 (bear) to A$0.6100 (bull), the price of A$0.3450 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Imexhs Ltd reported revenue of A$29.0M in FY2025 versus A$13.4M in FY2021, a compound +21.3%/yr. Reported net income was −A$2.9M in FY2025.
Key figures
Market cap A$18.7M (≈ $12.9M) Micro · P/E ratio 32.5 · P/S ratio 0.57 · Net margin 0.6% · Return on equity 1.2% · Return on assets (EBIT) −8.1% (5-year average) · Operating margin 0.9% · Revenue (TTM) A$31.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 38% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 1%, IME screens cheaper than that median.
Fair Value models
BearA$0.2300Fair Value A$0.3500BullA$0.6100
Price A$0.3450 · Upside +1.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+9.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.6%
Start year 2020 (pandemic). Over 10 years: +77.9% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.8%
’09
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−21.1% (2020) → −2.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about +26.5% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside+1.4% · Above median
Profitability
Return on equity (12 months)1.2% · Below median
Return on assets−12.2% · Bottom 25%
Net margin (12 months)0.6% · Below median
Operating margin (12 months)0.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)16.8% · Above median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Imexhs Ltd Fair Value". https://www.fairvalue-calculator.com/stock/IME
Frequently asked questions
Is Imexhs Ltd (IME) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of A$0.3500 versus a price of A$0.3450, about +1% upside (fairly valued).
What is the fair value of IME?
Our model-based fair value for Imexhs Ltd is A$0.3500 (as of Nov 7, 2026), built from audited fundamentals. The current price: A$0.3450.
What is the quality score of IME?
Imexhs Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Imexhs Ltd (IME)?
Our model-based price target is the fair value of A$0.3500 (as of Nov 7, 2026) from 9 valuation models. Cautious scenario A$0.2300, optimistic scenario A$0.6100. It is a calculation from audited fundamentals, not an analyst target.
What is the Imexhs Ltd stock forecast for 2026?
Our models put fair value at A$0.3500, about +1% upside versus a price of A$0.3450 (fairly valued). Cautious scenario A$0.2300, optimistic scenario A$0.6100. The calculation is refreshed regularly with new filings.
What is the revenue of Imexhs Ltd (IME)?
Imexhs Ltd reported trailing-twelve-month revenue of about A$31.3M (latest available figure, as of Nov 7, 2026).
What growth is priced into Imexhs Ltd (IME)?
For today's price to be fair in a discounted-cash-flow model, Imexhs Ltd would have to grow free cash flow by +30.3 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.6 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of IME use?
Our models discount Imexhs Ltd at 9.1 %: a base by market capitalisation (nano), damped by beta 0.84, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Imexhs Ltd that is +30.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Imexhs Ltd (IME) delivered so far?
Over the past 5 years revenue at Imexhs Ltd grew +21.6 % a year. The price currently implies free-cash-flow growth of +30.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Imexhs Ltd (IME) growing?
The median revenue growth in the sector is +11.5 % a year. That is the yardstick for the growth priced into Imexhs Ltd (+30.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Imexhs Ltd (IME)?
The free-cash-flow yield on the price is 1.31 %: that much free cash flow Imexhs Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Imexhs Ltd (IME)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Imexhs Ltd it is A$0.3500 per share (as of Nov 7, 2026), against a price of A$0.3450. It is the blended result of 9 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Imexhs Ltd stock overvalued or undervalued in 2026?
As of Nov 7, 2026, IME trades below its calculated fair value: price A$0.3450, fair value A$0.3500, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IME?
No. The price is what the market pays today (A$0.3450); the fair value is what the company's own numbers justify (A$0.3500). For Imexhs Ltd the two are A$0.0050 per share apart. That gap is exactly why we show both numbers side by side.
How much is Imexhs Ltd worth?
The market values Imexhs Ltd at about A$18.7M (market capitalisation, as of Nov 7, 2026). Per share that is A$0.3450; our models calculate a fair value of A$0.3500 per share.
What do the bullish and bearish scenarios say about IME?
Our models span a range for Imexhs Ltd: cautious scenario A$0.2300, base A$0.3500, optimistic A$0.6100 per share (as of Nov 7, 2026, price A$0.3450). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IME?
Imexhs Ltd trades at a price-to-earnings ratio of 32.5 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$0.3500 is built from several models across several years. Other multiples: P/B 0.8, P/S 0.4, EV/EBITDA 18.3.
How solid is the balance sheet of Imexhs Ltd (IME)?
Balance-sheet figures for Imexhs Ltd (as of Nov 7, 2026): return on equity 1.2%, debt of 0.00 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is IME from its 52-week high?
Imexhs Ltd trades at A$0.3450, about 27% below its 52-week high of A$0.4700 and 38% above the low of A$0.2500 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.3500 is for.
Which stocks are comparable to Imexhs Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Imexhs Ltd stock attractive at the current price?
The data as of Nov 7, 2026: price A$0.3450, calculated fair value A$0.3500 (+1%), Quality Score 41/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IME calculated?
We run Imexhs Ltd through 9 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of A$0.3500 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Imexhs Ltd currently trades 1% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Imexhs Ltd (IME)?
The closing price on Nov 6, 2026 was A$0.3450. Our model-based fair value is A$0.3500, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Imexhs Ltd right now?
The model range is unusually wide (A$0.2300 to A$0.6100). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Imexhs Ltd
How large is the market capitalisation of Imexhs Ltd (IME)?
The market capitalisation of Imexhs Ltd is A$18.7M (≈ $12.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Imexhs Ltd (IME)?
The price-to-sales ratio of Imexhs Ltd is 0.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Imexhs Ltd (IME)?
The net margin of Imexhs Ltd is 0.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Imexhs Ltd (IME)?
The return on equity (ROE) of Imexhs Ltd is 1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Imexhs Ltd (IME)?
On an EBIT basis the return on assets of Imexhs Ltd is −8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Imexhs Ltd (IME)?
The operating margin of Imexhs Ltd is 0.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Imexhs Ltd (IME)?
Revenue at Imexhs Ltd is growing +16.8% versus a year earlier (3y avg +19.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Imexhs Ltd (IME) hold?
Imexhs Ltd holds more cash than debt, A$2.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Imexhs Ltd in the live analysis
One click puts Imexhs Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026